Skip to main content

Table 1 Summary of studies on adjuvant chemotherapy in early-stage uterine sarcomas.

From: Treatment of early uterine sarcomas: disentangling adjuvant modalities

Study No of patients Radiation Regimens Recurrence (%) at 5 years 5-year survival (%)
Buchsbaum et al, 1979 [94] 8 NR VAC 37 63
Omura et al, 1985 [100] 64 No DOX 39 53
van Nagel et al, 1986 [95] 7 No VAC 29 86
Berchuck et al, 1988 [6] 12 LMS Yes Various 83 42
Piver et al, 1988 [105] 11 No CyVADIC 18 89
Hempling et al, 1995 [96] 20 No CyVADIC 35 68
Resnik et al, 1995 [101] 23 CS No Etoposide + cisplatin + DOX 22 92 (at 2 years)
Gadducci et al, 1996 [43] 11 LMS 2 patients Various 39 NR
Sartori et al, 1997 [106] 5 CS No NR 40 NR
Chauveinc et al, 1999 [21] 24 Yes Various NR NR
Kushner et al, 2000 [98] 10 No IFO 50 67 (at 3 years)
Manolitsas et al, 2001 [102] 21 CS Yes various 9.5 95
Giuntoli et al, 2003 [44] 34 LMS 2 patients Various NR NR
Pautier et al, 2004 [99] 16 Yes API 28 100
Odunsi et al, 2004 [97] 24 No CyVADIC 33 75
Sutton et al, 2005 [35] 65 CS No IFO + Cisplatin 35 62
Ti et al, 2006 [104] 51 Yes various 59 67
Papadimitriou et al, 2007 [4] 31 12 patients Anthracycline-based 39 54
Wolfson et al, 2007 [33] 101 CS No CIM 52 46